Literature DB >> 15834867

Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation.

Patricia Sastre1, José A Melero, Blanca García-Barreno, Concepción Palomo.   

Abstract

Antibodies directed against human respiratory syncytial virus (HRSV) glycoproteins were depleted from a commercial immunoglobulin preparation (RespiGam) by two different methods. The first method consisted of repeated adsorption of RespiGam to Sepharose beads with covalently bound soluble forms of the two major viral glycoproteins (F or G). The second method consisted of adsorption of immunoglobulins to live cells expressing F or G glycoproteins on their surfaces after infection with vaccinia virus recombinants. While the first method removed efficiently antibodies that reacted with F and/or G glycoproteins by ELISA, it was inefficient in the elimination of anti-HRSV neutralizing antibodies. In contrast, the second method removed efficiently anti-HRSV antibodies that both reacted by ELISA and neutralized virus infectivity. These results confirm that human neutralizing antibodies are directed exclusively against HRSV F and G glycoproteins, and, they raise the possibility that F and G glycoproteins inserted into cell membranes differ antigenically from their soluble forms linked covalently to Sepharose beads. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834867     DOI: 10.1002/jmv.20349

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

3.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

Review 4.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

5.  Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.

Authors:  Concepción Palomo; Vicente Mas; Michelle Thom; Mónica Vázquez; Olga Cano; María C Terrón; Daniel Luque; Geraldine Taylor; José A Melero
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

6.  A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.

Authors:  Kurt A Swanson; Kara Balabanis; Yuhong Xie; Yukti Aggarwal; Concepción Palomo; Vicente Mas; Claire Metrick; Hui Yang; Christine A Shaw; José A Melero; Philip R Dormitzer; Andrea Carfi
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

7.  The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein.

Authors:  Patricia Sastre; Antonius G P Oomens; Gail W Wertz
Journal:  Vaccine       Date:  2007-05-07       Impact factor: 3.641

8.  Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein.

Authors:  Morgan S A Gilman; Syed M Moin; Vicente Mas; Man Chen; Nita K Patel; Kari Kramer; Qing Zhu; Stephanie C Kabeche; Azad Kumar; Concepción Palomo; Tim Beaumont; Ulrich Baxa; Nancy D Ulbrandt; José A Melero; Barney S Graham; Jason S McLellan
Journal:  PLoS Pathog       Date:  2015-07-10       Impact factor: 6.823

9.  Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.

Authors:  Jessica A Flynn; Eberhard Durr; Ryan Swoyer; Pedro J Cejas; Melanie S Horton; Jennifer D Galli; Scott A Cosmi; Amy S Espeseth; Andrew J Bett; Lan Zhang
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

10.  Purification of polyclonal anti-conformational antibodies for use in affinity selection from random peptide phage display libraries: a study using the hydatid vaccine EG95.

Authors:  A J Read; C G Gauci; M W Lightowlers
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-28       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.